ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Houston Methodist

T. R. Mccarty

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

EADV 2024 Insights: Calciphylaxis

EADV 2024 Insights

C. Erfurt-Berge

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

New Research: Side Effect of GLP1

Susan Brian

Choosing the Optimal Blood Pressure Medication for My Hypertensive P…

Rivka Ayalon

2024 Updates on Checkpoint Inhibitor Toxicities: A Nephrology Lens

Cleveland Clinic Taussig Cancer Institute

A. Mehdi

An Introduction to Tirzepatide for Weightloss

Susan Brian

A New Paradigm: Rethinking Hypherphosphatemia Management

Icahn School of Medicine at Mount Sinai

D. Spiegel

Predictors of Poor Response to Semaglutide for Weight Management

Ploutarchos Tzoulis

Chapter 4 - How Can Primary Care Be Supported to Bridge the Chronic …

Springer Healthcare IME

S. Seidu, B. Itzhak, M. Ungan, L. Moist

Understanding the Phenomenon of 'Ozempic Face'

San Francisco Dermatological Society (SF Derm)

F. Kamangar

Artificial Intelligence & CHAT GPT in Nephrology

University of Colorado Department of Medicine

S. Ambruso

Etiology of Obesity

Beverly Tchang

CKD in Primary Care Full Webinar

Springer Healthcare IME

S. Seidu, B. Itzhak, M. Ungan, L. Moist

Treating Gout or Hyperuricemia in CKD Patients

Abdul Abdellatif

AUA 2024 Insights: " GLP-1 Receptor Agonists and Men's Health"

Insights from AUA 2024 Annual Meeting

E. Pozzi